Patient Outcomes Using the European Label for Dabigatran: A Post-Hoc Analysis From the RE-LY Database

Study Questions:

What is the efficacy and safety of dabigatran, when used according to the recommended dose regimen in the European (EU) label, as compared to well-controlled warfarin treatment (international normalized ratio [INR], 2-3; median time in therapeutic range, 67.3%)?